

Date: 25-02-2026

To,
The General Manager,
Department of Corporate Services
BSE Limited
Phiroze Jeejeebhoy Tower,
Dalal Street, Mumbai – 400001

To,
Manager – Listing,
Listing Department,
National Stock Exchange of India Limited,
Exchange Plaza, Bandra Kurla Complex,
Mumbai — 400051

Ref: Scrip Code at BSE: 533259 and NSE: SASTASUNDR

Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Execution of Share Purchase Agreement by Sastasundar Healthbuddy Limited, material subsidiary of the Company

Dear Sir/Madam,

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Company has received intimation from Sastasundar Healthbuddy Limited (“SHBL”), a material subsidiary of Health X Platform Limited (formerly known as Sastasundar Ventures Limited) (“Company”), that on February 25, 2026 a Share Purchase Agreement (“SPA”) has been executed between SHBL, Mitsubishi Corporation (“Seller”) and Envision India Fund (“Buyer”).

Pursuant to the aforesaid SPA, the Buyer shall acquire 10,13,766 (Ten Lakh Thirteen Thousand Seven Hundred Sixty Six) Equity Shares, representing 4.68% of total issued and paid-up share capital of SHBL from the Seller, at a price of Rs. 493.21 per share, aggregating to total consideration of Rs. 49,99,99,528.86 subject to the satisfaction of the agreed terms and conditions as stipulated in the SPA.

Consequent to completion of above acquisition of shares by the buyer, the Seller shall cease to be the shareholder of the SHBL.

The Company has received the aforesaid information from SHBL on February 25, 2026 at 7:57 P.M.

Yours faithfully,

For Health X Platform Limited
(formerly known as Sastasundar Ventures Limited)

Pratap Singh
Company Secretary & Compliance Officer
M. No. A24081